In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 9, 2000, Pages 2319-2326

  Gong, Y F ^a   Robinson, B S ^a   Rose, R E ^a   Deminie, C ^a   Spicer, T P ^a   Stock, D ^a   Colonno, R J ^a   Lin, P F ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; ARTICLE; CROSS RESISTANCE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRUS ISOLATION;

AMINO ACID SEQUENCE; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; MUTATION; OLIGOPEPTIDES; PYRIDINES; SEQUENCE HOMOLOGY, AMINO ACID; SUBSTRATE SPECIFICITY;

EID: 0033844808     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.9.2319-2326.2000     Document Type: Article

References (46)

1. Resistance to human immunodeficiency virus type 1 protease inhibitors
2. Ritonavir and saquinavir combination therapy for the treatment of HIV infection
3. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor
4. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
5. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
6. HIV protease genotype and viral sensitivity to HIV protcasc inhibitors following saquinavir therapy
7. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase
8. Novel gag-pol frameshift site in human immunodeficiency virus type 1 variants resistant to protease inhibitors
9. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors
10. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy
11. Resistance of HIV type 1 to proteinase inhibitor Ro 31-8959
12. HIV-protease inhibitors
13. Current antiretroviral therapy: An overview
14. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
15. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959
16. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: Mutations, kinetics, and frequencies
17. Infectivity assay (virus yield assay)
18. The retroviral enzymes
19. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans
20. Genotypic and phenotypic analysis of human immunodeficiency virus type I isolates from patients on prolonged stavudine therapy
21. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients
22. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor
23. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV-1) protease, to treat HIV infection
24. Human immunodeficiency virus type 1 protease inhibitors
25. Recent developments in HIV protease inhibitor therapy
26. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
27. Antiretroviral therapies in HIV-1 infection
28. Current knowledge and future prospects for the use of HIV protease inhibitors
29. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infections. AIDS Clinical Trials Group 347 Study Team
30. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease
31. Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor
32. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease
33. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir
34. 'Mini' reverse transcriptase (RT) assay
35. Human immunodeficiency virus type 1 virus background plays a major role in development of resistance to protease inhibitors
36. + T-cell counts in HIV-infected patients
37. Mutations in retroviral genes associated with drug resistance
38. Resistance related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538)
39. A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A
40. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors
41. L-735,524: An orally bioavailable human immunodeficiency virus type 1 protease inhibitor
42. Clinically effective HIV-1 protease inhibitors
43. Advances in the medical management of patients with HIV-1 infection: An overview
44. New soluble-formazan assay for HIV-1 cytopathic effects: Application to high-flux screening of synthetic and natural products for AIDS-antiviral activity
45. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites
46. The N88S mutation in HIV-1 protease is associated with increased susceptibility to amprenavir